As these PrPC domains have been revealed as putative pharmacological targets for Alzheimer’s disease [65–67], our data might also enhance the eligibility of PrPC as a putative target to modulate α-synuclein expansion. Here, PRNP is linked to early-onset autosomal dominant Alzheimer disease.